Tirzepatide in Australia

Dual GIP and GLP-1 receptor agonist. Tirzepatide is a 39-amino-acid peptide that activates both the GIP and GLP-1 receptors. It is the first dual incretin agonist to complete Phase 3 development and is registered in many countries as a prescription medicine. The research-grade vial supplied here is the unformulated peptide for laboratory use, not the branded pen.

Glycaemic control: hbA1c and fasting glucose across the SURPASS trials. Body composition: fat mass versus lean mass in DEXA sub-studies. Appetite signalling: food intake and satiety measures in Phase 1 pharmacology. Hepatic fat: liver-fat fraction by MRI-PDFF in MASLD studies. Cardiovascular outcomes: sURPASS-CVOT and SUMMIT programs. The SURPASS program in type 2 diabetes and the SURMOUNT program in obesity reported HbA1c reductions of around 2 percentage points and mean weight reductions of up to 22.5% at the highest dose over 72 weeks (SURMOUNT-1, Jastreboff et al., NEJM 2022). Later studies examined sleep apnoea, heart failure with preserved ejection fraction and MASLD.

SURMOUNT-1 reported mean weight reductions of 15.0%, 19.5% and 20.9% at 5, 10 and 15mg weekly over 72 weeks (22.5% on the treatment-regimen estimand) versus 3.1% on placebo; SURPASS trials reported HbA1c reductions of about 2 percentage points. Body-composition sub-studies attributed roughly three quarters of weight lost to fat mass.

Gastrointestinal events (nausea, diarrhoea, decreased appetite, vomiting, constipation) were the most common in the trials, mostly mild to moderate and occurring during dose escalation. Registered-product labelling carries warnings on pancreatitis, gallbladder disease, hypoglycaemia with insulin secretagogues and a thyroid C-cell tumour boxed warning based on rodent data.

Published Tirzepatide studies specify their own amounts and routes, and those vary by model and endpoint. Peptide Aus products are supplied for in-vitro laboratory research, so we do not provide dosing, cycle or usage guidance for people. For laboratory preparation, the reconstitution calculator converts vial size and water volume into concentration and syringe units.

Retatrutide adds glucagon receptor activity to tirzepatide's GLP-1 and GIP profile and reported larger weight loss in its Phase 2 trial; tirzepatide is the one that is registered as a medicine.

SURPASS-2 compared them directly in type 2 diabetes: tirzepatide produced greater HbA1c and weight reductions than semaglutide 1mg at all three doses.

Mounjaro is the registered tirzepatide pen for prescription use. The research vial is the same peptide as unformulated lyophilised powder for laboratory work and is not a substitute for it.

It is the same active peptide, but it is not the same product. Mounjaro is a registered, sterile, dose-metered injection manufactured under pharmaceutical GMP for prescription use. This vial is unformulated research-grade tirzepatide for laboratory study and is not a substitute for a prescribed medicine.

The 20mg vial suits short assays and method development. The 40mg and 60mg vials reduce the number of reconstitutions across a longer protocol and cost less per milligram. Each size has its own certificate of analysis.

With bacteriostatic water added slowly down the inside wall of the vial, then swirled gently. Each vial size lists its suggested volume, and the calculator converts volume to concentration.

Lyophilised: −20 °C, sealed, away from light and moisture. Reconstituted: 2–8 °C, used within 8–12 weeks, never frozen.

Tirzepatide is a Schedule 4 prescription-only medicine in Australia when supplied as the registered product. Research-grade tirzepatide powder is not that product and is not approved for human use. Peptide Aus supplies it for in-vitro laboratory research only.

Directly from Peptide Aus, from Australian stock, in 3 vial sizes from $249.99 (20mg) to $349.99 (60mg). Prices are AUD and GST inclusive. Paid orders before 2pm AEST/AEDT dispatch the same business day, tracked.